Renal Anemia Market Research Report By Anemia Type (Iron Deficiency Anemia, Vitamin B12 Deficiency Anemia, Folate Deficiency Anemia, Aplastic Anemia, Hemolytic Anemia, Sickle Cell Anemia), By Treatment Type (Erythropoiesis-Stimulating Agents (ESAs), Iron Supplementation, Vitamin B12 Supplementation, Folate Supplementation, Transfusion Therapy, Bone Marrow Transplant), By Disease Severity (Mild, Moderate, Severe), By End-User (Hospitals, Dialysis Centers, Clinics, Home Healthcare), By Route of Administration (Intravenous, Subcutaneous, Oral)

Global Renal Anemia Market Overview

As per MRFR analysis, the Renal Anemia Market Size was estimated at 2.02(USD Billion) in 2022.The Renal Anemia Market Industry is expected to grow from 2.14(USD Billion) in 2023 to 3.6(USD Billion) by 2032. The Renal Anemia Market CAGR (growth rate) is expected to be around 5.94% during the forecast period (2024 - 2032).

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Key Renal Anemia Market Trends Highlighted

The Global Renal Anemia Market is experiencing transformative shifts, primarily driven by technological advancements in diagnostics and advancements in erythropoiesis-stimulating agents (ESAs). The increasing prevalence of chronic kidney disease (CKD), coupled with growing awareness and early detection initiatives, is fueling demand for renal anemia treatments.Key market drivers include the growing burden of CKD, advancements in early detection and diagnosis, and the emergence of innovative therapies. Opportunities for exploration lie in the development of non-ESA-based therapies, targeted drug delivery systems, and personalized treatment regimens.Recent trends in the market include a shift towards early intervention to prevent disease progression, the adoption of combination therapies, and the integration of artificial intelligence in disease management. The market is also witnessing the emergence of biosimilars, offering cost-effective treatment options and expanding access to therapy. Regulatory approvals for novel therapies and the expansion of reimbursement policies are expected to further drive growth in the Renal Anemia Market.

Renal Anemia Market Drivers

Increasing Prevalence of Chronic Kidney Disease (CKD)

A major risk factor for developing renal anemia is chronic kidney disease. With the inclination in the CKD prevalence globally, the need for a treatment option for renal anemia is expected to surge. According to the National Kidney Foundation, about 37 million adults across the United States have CKD. The figure is expected to climb to 47 million come 2030. Thus, one of the key reasons there is growth in the Global Renal Anemia Market Industry is due to the inclining CKD incidence.

Growing Adoption of Erythropoiesis-Stimulating Agents (ESAs)

ESAs are class drugs that stimulate the production of red blood cells. These are currently approved for the treatment of renal anemia and are the standard of care. Low hemoglobin levels can be managed and help to diagnose certain conditions. With the increasing usage of ESAs, there is remarkable growth in the Global Renal Anemia Market Industry.

Rising Demand for Non-Invasive Treatment Options

There is a danger of death occurring to the fetus if the use of the Tat gene in the above studies is allowed. This is because the inhibition of placental invasion would prevent the attachment of the placenta to the womb. The fetus and the placenta get their food supply from the spongy womb of the host, being eroded away by the proteins of the invader. It is, therefore, imperative that the processes leading to the intervention of placental invasion be controlled and stopped.

Renal Anemia Market Segment Insights

Renal Anemia Market Anemia Type Insights

The Global Renal Anemia Market is segmented by anemia type into Iron Deficiency Anemia, Vitamin B12 Deficiency Anemia, Folate Deficiency Anemia, Aplastic Anemia, Hemolytic Anemia, and Sickle Cell Anemia. Iron Deficiency Anemia is the most common type of anemia, accounting for about 50% of all cases. Iron is a crucial element in the body because it is used to make hemoglobin, the protein in red blood cells responsible for carrying oxygen. When the body has too little iron to produce hemoglobin, one gets this type of anemia. Some of the reasons that cause iron deficiency are blood loss, deficient intake of iron, or body demands such as pregnancy or certain medical conditions.On the other hand, Vitamin B12 Deficiency Anemia arises when there is insufficient B12 or cobalamin, which is essential for the production of red blood cells. The decrease in Vitamin B12 in the body may be stimulated by pernicious anemia-for this disorder, the body cannot ingest Vitamin B12 from food. In addition, Folate Deficiency Anemia is a deficiency of Folic acid, which is necessary in the production of red blood cells. The only thing is that Folic acid comes from a variety of differences, such as pregnancy, breastfeeding, and certain medical conditions.Aplastic Anemia is a condition where the production of blood cells is decreased-white blood cells, platelets, and red blood cells. It is not clear about the specific cause of this condition, though there can be factors such as certain medications, viral infections, or autoimmune disorders. In addition, Hemolytic Anemia is the destruction of red blood cells. Factors that can cause hemolytic anemia are some types of autoimmune disorders, genetic disorders, and certain medications. Lastly, Sickle Cell Anemia is a disease that occurs due to a defect in the shape of red blood cells.Sickle-shaped cells can hinder the transfer of blood in one’s body, causing a wide range of problems such as pain, organ damage and stroke. There are various reasons attributing to this growth; first, the market is proliferating because anemia ailment is becoming rampant. Secondly, more people are demanding blood from healthy individuals. Also, new drugs have been discovered that can heal most forms of anemia in the human body.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Renal Anemia Market Treatment Type Insights

The Treatment Type segment of the Global Renal Anemia market is split into the Erythropoiesis-Stimulating Agents segment, Iron Supplementation segment, Vitamin B12 Supplementation segment, Folate Supplementation segment, Transfusion Therapy segment, and Bone Marrow Transplant segment. The ESA segment is expected to dominate the market in 2023, and it is likely to continue to do so over the forecast period. The dominance of the ESA segment is attributed to the rising incidence of chronic kidney disease CDS, resulting in a decrease in the number of red blood cells produced.Therefore, ESAs are used to stimulate the production of red blood cells in patients suffering from anemia. The Iron Supplementation segment is expected to grow at a steady rate over the forecast period.

The increasing awareness of the importance of iron in treating renal anemia accounts for its growth. Iron is required in the formation of hemoglobin, which is a component of red blood cells that is responsible for transporting oxygen from the lungs to the body tissues and removing harmful carbon dioxide from the blood. The Vitamin B12 Supplementation segment is expected to grow at a significant rate over the forecast period.The increasing incidence of vitamin B12 deficiency in patients being treated for renal anemia accounts for its growth. Vitamin B12 is important in the process of forming red blood cells and ensuring the proper functioning of the nerve. The Folate Supplementation segment is expected to grow at a moderate rate over the period of the forecast. The awareness of the importance of folate in treating renal anemia is increasing, hence, the growth. Folate is used as a source of folic acid in the formation of DNA and red blood cells. The Transfusion Therapy segment is expected to grow at a steady rate over the forecast period.The increasing incidence of renal anemia has led to a rising number of patients, who require transfusion of blood from a donor to boost their red blood cells.

The Bone Marrow Transplant segment is expected to grow at a moderate rate over the forecast period as a result of the high cost and technical requirements for the procedure. The segment involves the transplantation of healthy bone marrow from a donor to a patient being treated for renal anemia. The procedure is used in the case of a patient with severe renal anemia who has not responded to other treatment options.

Renal Anemia Market Disease Severity Insights

The Global Renal Anemia Market is segmented by disease severity into mild, moderate, and severe. Among these segments, the severe segment is expected to hold the largest market share in the coming years. This is due to the increasing prevalence of chronic kidney disease (CKD), which is a major risk factor for developing severe renal anemia. In 2023, the severe segment held a market share of approximately 45%. By 2032, this share is expected to increase to over 50%. The moderate segment is expected to hold the second-largest market share, followed by the mild segment.The growth of the moderate and severe segments is expected to be driven by the increasing adoption of erythropoiesis-stimulating agents (ESAs) and other treatments for renal anemia.

Renal Anemia Market End-User Insights

The Global Renal Anemia Market segmentation by End-User comprises Hospitals, Dialysis Centers, Clinics, and Home Healthcare. Hospitals held the dominant position in the market in 2023 and accounted for over 55% of the Global Renal Anemia Market revenue. The large number of patients suffering from renal anemia undergoing treatment in hospitals contributes to this segment's growth. Dialysis Centers accounted for the second-largest share, followed by Clinics and Home Healthcare. The growing adoption of home-based dialysis therapies is expected to drive the growth of the Home Healthcare segment in the coming years.The increasing prevalence of chronic kidney disease (CKD) and the rising demand for effective treatments for renal anemia are major factors driving the growth of the Renal Anemia Market.

Renal Anemia Market Route of Administration Insights

The Global Renal Anemia Market segmentation by Route of Administration comprises Intravenous, Subcutaneous, and Oral. Intravenous administration held the largest market share in 2023 due to its high efficacy and rapid onset of action. Subcutaneous administration is expected to exhibit the fastest CAGR of 6.2% during the forecast period, owing to its convenience and ease of administration. Oral administration is projected to witness steady growth due to its non-invasive nature and cost-effectiveness. The Global Renal Anemia Market is driven by the rising prevalence of chronic kidney disease, increasing demand for effective treatments, and growing awareness about the benefits of early diagnosis and management.The market is also fueled by the introduction of novel therapies and the expansion of healthcare infrastructure in developing regions. The increasing investment in research and development activities is further contributing to the market growth.

Renal Anemia Market Regional Insights

The Global Renal Anemia Market is segmented into North America, Europe, APAC, South America, and MEA. North America is expected to hold the largest market share in 2023, with a market value of USD 0.86 billion. Europe is expected to follow North America, with a market value of USD 0.61 billion in 2023. APAC is expected to be the fastest-growing regional market, with a CAGR of 7.2% during the forecast period. The growth in APAC is attributed to the increasing prevalence of chronic kidney disease and the rising demand for dialysis treatments in the region.South America and MEA are expected to account for a smaller share of the global market.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Renal Anemia Market Key Players And Competitive Insights

The Global Renal Anemia Market is a highly competitive market with a large number of well-established players as well as emerging market players. Amgen, AstraZeneca, and Roche are some of the greatest major players in the Renal Anemia Market and constitute a large part of the market revenue. All the major players in the Renal Anemia Market are continuously involved in the research and development of product innovation, market expansions to broaden their geographic reach, and acquisitions to strengthen their market position.The Renal Anemia Market is marked by constant innovation, which includes the introduction of newer treatment methodologies and the advent of personalized medicines.I exemplify Amgen, a frontrunner major competitor of the Global Renal Anemia Market and a major biotechnology innovator company.

Amgen’s offering in the Renal Anemia Market includes the recombinant EPO Epogen and Aranesp. Ignoring the recessionary conditions to a large extent, Amgen is a worldwide leader in the biotechnology industry. It is an innovative and research-oriented biotechnology company whose EPO product is widely used as it is effective not only in the production of red blood cells but also in the correction of anemia. Its global presence and an excellent distribution network ensure that products reach every part of the globe and a wider customer reach. The company has launched innumerable ESAs after its initial EPO launch, and continuous research has led to more effective ESAs launched in recent times with reduced side effects.AstraZeneca is also a major player in the Renal Anemia Market and a major competitor. The renal anemia product offered by AstraZeneca is Mircera. Mircera is a long-acting ESA, which ensures that hemoglobin control is sustained and the frequency of injections is down. It is entirely possible that Amgen will become a major competitor of AstraZeneca and a great threat at some point in the future.

Key Companies in the Renal Anemia Market Include

• Roche


• AstraZeneca PLC


• Fresenius Medical Care AG Co. KGAA


• Johnson Johnson


• Astellas Pharma Inc.


• Amgen Inc.


• Otsuka Pharmaceutical Co., Ltd.


• Merck Co., Inc.


• Teva Pharmaceutical Industries Ltd.


• Novartis AG


• AbbVie Inc.


• Sanofi


• Pfizer Inc.


• Baxter International Inc.

Renal Anemia Market Industry Developments

The global renal anemia market is expected to witness steady growth over the forecast period, driven by the rising prevalence of chronic kidney disease (CKD) and increasing adoption of erythropoiesis-stimulating agents (ESAs). Key developments in the market include:- New drug approvals: Several new drugs have been approved for the treatment of renal anemia, including luspatercept and roxadustat. These drugs offer advantages over traditional ESAs, such as improved efficacy and reduced side effects.- Launch of biosimilars: The launch of biosimilars for ESAs has increased competition and lowered costs, making treatment more accessible for patients.- Rising demand for home dialysis: The growing popularity of home dialysis has led to increased demand for erythropoiesis-stimulating agents, as patients on home dialysis require more frequent dosing.- Government initiatives: Governments worldwide are implementing various initiatives to improve access to treatment for renal anemia, including reimbursement programs and patient support groups.These factors are expected to contribute to the growth of the global renal anemia market in the coming years.

Renal Anemia Market Segmentation Insights

• 
  

  Renal Anemia Market Anemia Type Outlook

  
  
  
  
  • Iron Deficiency Anemia
  
  
  • Vitamin B12 Deficiency Anemia
  
  
  • Folate Deficiency Anemia
  
  
  • Aplastic Anemia
  
  
  • Hemolytic Anemia
  
  
  • Sickle Cell Anemia
  
  
  
  

• 
  

  Renal Anemia Market Treatment Type Outlook

  
  
  
  
  • Erythropoiesis-Stimulating Agents (ESAs)
  
  
  • Iron Supplementation
  
  
  • Vitamin B12 Supplementation
  
  
  • Folate Supplementation
  
  
  • Transfusion Therapy
  
  
  • Bone Marrow Transplant
  
  
  
  

• 
  

  Renal Anemia Market Disease Severity Outlook

  
  
  
  
  • Mild
  
  
  • Moderate
  
  
  • Severe
  
  
  
  

• 
  

  Renal Anemia Market End-User Outlook

  
  
  
  
  • Hospitals
  
  
  • Dialysis Centers
  
  
  • Clinics
  
  
  • Home Healthcare
  
  
  
  

• 
  

  Renal Anemia Market Route of Administration Outlook

  
  
  
  
  • Intravenous
  
  
  • Subcutaneous
  
  
  • Oral
  
  
  
  

• 
  

  Renal Anemia Market Regional Outlook

  
  
  
  
  • North America
  
  
  • Europe
  
  
  • South America
  
  
  • Asia Pacific
  
  
  • Middle East and Africa